Meitheal Pharmaceuticals (Meitheal) is pleased to announce the official launch of IDArubicin Hydrochloride Injection, USP:
- 71288-184-05 – IDArubicin Hydrochloride Injection, USP 5 mg per 5 mL
- 71288-185-10 – IDArubicin Hydrochloride Injection, USP 10 mg per 10 mL
- 71288-186-20 – IDArubicin Hydrochloride Injection, USP 20 mg per 20 mL
ABOUT IDArubicin Hydrochloride Injection, USP
IDArubicin Hydrochloride Injection, USP is indicated for treatment of acute myeloid leukemia (AML) in adults in combination with other approved antileukemic drugs. This includes French-American-British classifications M1 through M7.
For full prescribing information, please click on the following link.
Learn more about who we are and what we do at: www.meithealpharma.com.
